Video

EirGenix Inc. Capacity Update February 2024: Large Molecule

EirGenix is Taiwan's largest CDMO for mammalian and microbial-derived, clinical, and commercial manufacturing of biologics (mAbs, bi-specifics, ADC, vaccines, and pDNA). EirGenix is inspected and approved by the USFDA, Japan PMDA, Australia TGA, and the EU EMA. EirGenix has immediate availability of capacity up to 12 x 2,000 L SUBs for mammalian cells and up to 150 L scale for microbial and that will increase to 350L and 1,000L by end of this year.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

EirGenix Inc.